Cologne, Germany

Alfons Carcasona

This inventor holds 5 USPTO granted patents. Top assignees: Madaus Ag, Laboratoire Medidom Sa. Active years: 1995-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alfons Carcasona. Retrieved from https://idiyas.com/inventor/alfons-carcasona

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Cologne, DE (1995)
  • Koln, DE (1995 - 1998)
  • Köln, DE (2003)

Company Filing History:


Years Active: 1995-2003

Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Journey of Alfons Carcasona

Introduction: Alfons Carcasona, a distinguished inventor hailing from Köln, Germany, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Alfons Carcasona's latest patents include a cutting-edge software application for optimizing energy consumption in smart homes and a revolutionary medical device for non-invasive glucose monitoring.

Career Highlights: Throughout his illustrious career, Alfons Carcasona has been recognized for his exceptional problem-solving skills and creativity, leading to the development of several pioneering technologies that have improved the lives of many.

Collaborations: Alfons Carcasona has collaborated with leading research institutions and tech companies to bring his ideas to life, fostering a culture of innovation and excellence in every project he undertakes.

Conclusion: Alfons Carcasona's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…